Funding, News and Announcements
» Go to news mainPfizer: Research in Ulcerative Colitis (UC) 2024
This competitive program seeks to support global research that helps to address Ulcerative Colitis data gaps and advances the understanding of etrasimod and / or tofacitinib role in the treatment landscape.
Potential applicants are encouraged to identify and address the data gaps and advances understanding the role of etrasimod and tofacitinib in UC treatment landscape. This may include
- Exploration for optimal ultrasonographic markers
- Evaluation of UC extraintestinal manifestations
- Evaluation in specific subgroups of special interest
- Evaluation of advanced therapy sequencing strategy
Funding Range and Project Length: Individual projects requesting up to USD 200,000 will be considered. The project length will be a maximum of eighteen (18) months.
Contact Details
Internal: ird@dal.ca
External: Amanda Stein (amanda.j.stein@pfizer.com) with the subject line 鈥淩esearch in Ulcerative Colitis (UC) 2024.鈥
Deadlines
Internal: July 22, 2024
External: August 5, 2024
听
The听grants facilitator听for your faculty can be found on the staff contact page. For additional resources,听click here for guidance听on internal deadlines and submission processes.
Recent News
- The Association of Commonwealth Universities (ACU) Funding Opportunities 2024鈥25
- Social Sciences and Humanities Research Council
- Global Research Fund
- Genome Canada
- NS鈥慤SA Subsea Cable Socioeconomic Study
- CIHR Institute of Cancer Research
- Webinar in Equity, Diversity and Inclusion (EDI)
- Nova Scotia Office of Addictions and Mental Health